Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.
BACKGROUND
Studies by comparative genomic hybridization (CGH) have shown that chromosomal region 17q23 is amplified in up to 20% of primary breast cancers. We used microarray analyses to measure the expression levels of genes in this region and to explore their prognostic importance.


METHODS
A microarray that contained 4209 complementary DNA (cDNA) clones was used to identify genes that are overexpressed in the MCF-7 breast cancer cell line as compared with normal mammary tissue. Fluorescence in situ hybridization was used to analyze the copy number of one overexpressed gene, ribosomal protein S6 kinase (S6K), and to localize it to the 17q23 region. Northern and western blot analyses were used to measure S6K gene and protein expression, and an enzymatic assay was used to measure S6K activity. Tumor tissue microarray analysis was used to study amplification of S6K and the HER-2 oncogene, another 17q-linked gene, and the relationship between amplification and prognosis was analyzed. The Kaplan-Meier method was used for data analysis, and the log-rank test was used for statistical analysis. All P values are two-sided.


RESULTS
S6K was amplified and highly overexpressed in MCF-7 cells relative to normal mammary epithelium, and protein expression and enzyme activity were increased. S6K was amplified in 59 (8.8%) of 668 primary breast tumors, and a statistically significant association between amplification and poor prognosis (P =.0021) was observed. Amplification of both S6K and HER-2 implied particularly poor survival (P =.0001).


CONCLUSIONS
The combination of CGH information with cDNA and tissue microarray analyses can be used to identify amplified and overexpressed genes and to evaluate the clinical implications of such genes and genomic rearrangements. S6K is likely to be one of the genes at 17q23 that is amplified during oncogenesis and may adversely affect the prognosis of patients with this amplification.
Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
M
M
Bärlund
F
F
Forozan
J
J
Kononen
L
L
Bubendorf
Y
Y
Chen
M L
ML
Bittner
J
J
Torhorst
P
P
Haas
C
C
Bucher
G
G
Sauter
O P
OP
Kallioniemi
A
A
Kallioniemi
D015152:Blotting, Northern; D015153:Blotting, Western; D001940:Breast / Q000201:enzymology; D001943:Breast Neoplasms / Q000201:enzymology* / Q000235:genetics*; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D018076:DNA, Complementary; D004273:DNA, Neoplasm / Q000032:analysis*; D004789:Enzyme Activation; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic; D018734:Genes, erbB-2 / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D019893:Ribosomal Protein S6 Kinases / Q000235:genetics / Q000378:metabolism*; D016019:Survival Analysis; D014407:Tumor Cells, Cultured; D015854:Up-Regulation
D018076:DNA, Complementary; D004273:DNA, Neoplasm; D019893:Ribosomal Protein S6 Kinases